A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®
Status:
Completed
Trial end date:
2003-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to prospectively assess the relationship between changes in
hemoglobin (hgb) and changes in symptom burden associated with anemia in cancer patients
receiving chemotherapy supported with Aranesp®.